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ORIGINAL ARTICLE
534Risk of Serious Infection in Patients with
Psoriasis Receiving Biologic Therapies:
A Prospective Cohort Study from the British
Association of Dermatologists Biologic
Interventions Register (BADBIR)
Zenas Z.N. Yiu1,2, Catherine H. Smith3, Darren M. Ashcroft2, Mark Lunt4, Shernaz Walton5,
Ruth Murphy6, Nick J. Reynolds7, Anthony D. Ormerod8,9, Christopher E.M. Griffiths1,9 and
Richard B. Warren1,9, BADBIR Study GroupSerious infection is a concern for patients with psoriasis receiving biologic therapies. We assessed the risk of
serious infections for biologics used to treat psoriasis by comparison with a cohort receiving non-biologic
systemic therapies in a propensity score-weighted Cox proportional hazards model using data from the
British Association of Dermatologists Biologic Interventions Register. Overall, 1,352; 3,271; and 994 participants
were included in the etanercept, adalimumab, ustekinumab cohorts, respectively, and 3,421 participants were
in the non-biologic cohort. A total of 283 patients had a serious infection; the incidence rates with 95% con-
fidence intervals (CI) per 1,000 person-years were as follows: non-biologic, 14.2 (11.5e17.4); etanercept, 15.3
(11.6e20.1); adalimumab, 13.9 (11.4e16.6); and ustekinumab, 15.1 (10.8e21.1). No significant increases in the risk
of serious infection were observed for etanercept (hazard ratio [HR] ¼ 1.10, 95% CI ¼ 0.75e1.60), adalimumab
(HR ¼ 0.93, 95% CI ¼ 0.69e1.26), or ustekinumab (HR ¼ 0.92, 95% CI ¼ 0.60e1.41) compared with non-biologic
systemic therapies or methotrexate-only (etanercept: HR ¼ 1.47, 95% CI ¼ 0.95e2.28; adalimumab: HR ¼ 1.26,
95% CI ¼ 0.86e1.84; ustekinumab: HR ¼ 1.22, 95% CI ¼ 0.75e1.99). The risk of serious infection should not be a
key discriminator for patients and clinicians when choosing between non-biologic systemic therapies, eta-
nercept, adalimumab, and ustekinumab for the treatment of psoriasis.
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Moderate to severe psoriasis is increasingly managed by
biologic, immune-modulating therapies. The main adverse
event leading to discontinuation of biologic therapies in
patients with psoriasis is infection (Warren et al., 2015).
Serious infections are associated with significant morbidity or
mortality. Thus, patients considering the switch from less
effective non-biologic systemic therapies to biologic thera-
pies are concerned about whether these treatments are
associated with a greater risk of serious infections.
The risk of serious infection for biologic therapies in the
real world has been hard to ascertain, because clinical trials
have limited external validity (Garcia-Doval et al., 2012) and
are not powered to assess this outcome (Yiu et al., 2016).
Currently, the risk of serious infections in patients with pso-
riasis on biologic therapies is not well-quantified. Three
prospective observational cohort studies, using different
methodologies and different comparators, have unsurpris-
ingly reported conflicting results (Davila-Seijo et al., 2017;
Garcia-Doval et al., 2017a; Kalb et al., 2015). One showed
no increased risk of serious infection with tumor necrosis
factor inhibitors (TNFIs) compared with acitretin, metho-
trexate, or cyclosporine (Garcia-Doval et al., 2017b), and the
two other studies showed no significant increased risk with
TNFIs or ustekinumab versus methotrexate (Davila-Seijos. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Participant inclusion and exclusion flow diagram. BADBIR, British
Association of Dermatologists Biologic Interventions Register.
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infliximab compared with retinoids/phototherapy (Kalb et al.,
2015). However, these studies have different specific limita-
tions—for example, a smaller sample size and lack of power
to investigate serious infections (Davila-Seijo et al., 2017),
limited analytical methodology in adjusting for potential
confounders (Kalb et al., 2015), and inclusion of TNFIs only
(Garcia-Doval et al., 2017a)—which may have accounted for
the contradictory results.
Our objective was to determine whether the biologic
therapies recommended by the National Institute for Health
and Care Excellence in the UK for patients with moderate to
severe psoriasis (defined as Psoriasis Area and Severity Index
of at least 10 and Dermatology Life Quality Index of more
than 10)—etanercept, adalimumab, or ustekinumab—elevate
the risk of serious infection more than non-biologic systemic
therapies in patients with psoriasis. To address this, we used a
large, national, prospective psoriasis registry, the British
Association of Dermatologists Biologic Interventions Register
(BADBIR).
RESULTS
A total of 9,038 participants were included for analysis
(Figure 1), with 3,421 participants included in the non-
biologic systemic cohort and 5,617 participants included
in the biologic cohort through October 2016. The number
of participants lost to follow-up at each data collection
point is listed in Supplementary Table S1 online. The
baseline demographic, anthropometric, and disease char-
acteristics of the participants are listed in Table 1. The total
and median follow-up times for the biologic therapies
were 13,369.81 and 1.95 person-years (interquartile range
[IQR] ¼ 2.24 person-years), respectively. Adalimumab had
the longest total person-time follow-up of 7,835.17
person-years and ustekinumab the shortest, at 2,256.44
person-years (Table 2). The total person-time follow-up
and median follow-up times for the non-biologic cohort
were 6,419.24 person-years and 1.51 (IQR ¼ 1.84 person-
years) person-years, respectively.
Crude incidence rates for serious infections overall
The incidence rate for serious infections per 1,000 person-
years in the non-biologic cohort was 14.18 (95% confi-
dence interval [CI] ¼ 11.54e17.41), with the incidence rate
for the methotrexate-only cohort at 11.98 (95% CI ¼
8.82e16.27). The crude incidence rates per 1,000 person-
years in the biologic cohorts were etanercept, 15.25 (95%
CI ¼ 11.56e20.11); adalimumab, 13.78 (95% CI ¼
11.41e16.64); and ustekinumab, 15.07 (95% CI ¼
10.77e21.09).
Nature of the serious infections
The most common Medical Dictionary for Regulatory
Activities (i.e., MedDRA) high level term-coded serious
infections experienced by participants receiving either
non-biologic systemic therapy or biologic therapies were
lower respiratory tract infections, followed by skin and soft
tissue infections and urinary tract infections (see
Supplementary Table S2 online). The crude incidence rates
for serious lower respiratory tract infections and skin/soft
tissue infections are presented in Table 2. Where theorganism responsible for the serious infection was given or
identified, the most common MedDRA high level term
code was staphylococcal infections with 13 events,
followed by streptococcal infections with 10 events (see
Supplementary Table S3 online). There were five tubercu-
lous infections and four herpes viral infections (herpes
zoster infections). The median hospital inpatient stay
ranged from 3 days (IQR ¼ 6.0) for non-biologic therapies
to 5 days for etanercept (IQR ¼ 8.0) and adalimumab
(IQR ¼ 11.0) (see Supplementary Table S4 online). Seven
participants died within 30 days of the serious infection in
the non-biologic cohort; the 30-day mortality rate for
etanercept was less than 5, and there were no deaths
within 30 days of the event for adalimumab or
ustekinumab.
Propensity score-weighted models for the risk of serious
infections
The inverse probability treatment-weighted multinomial
model involving the non-biologic, etanercept, adalimumab,
and ustekinumab cohorts achieved good balance, removing
expected bias for most of the variables (see Supplementary
Table S5 online), suggesting a reduction of confounding
from these variables.
No biologic therapy showed a statistically significant
increase in the risk of serious infection compared with non-
biologic systemic therapies, although the risk estimate for
etanercept (hazard ratio [HR] ¼ 1.10, 95% CI ¼ 0.75e1.60)
was above 1 (Table 3). The proportionality assumption was
met for etanercept and adalimumab but not for ustekinumab
in the multinomial model.
Analysis split by a priori defined follow-up time found a
nonstatistically significant increase in risk of serious
infection in the first 6 months compared with non-biologicwww.jidonline.org 535
Table 1. The baseline demographic and disease characteristics of the study cohort
Patient Characteristics
Non-biologic
cohort
(n [ 3,421)
Etanercept
(n[ 1,352)
Adalimumab
(n [ 3,271)
Ustekinumab
(n [ 994)
Demographics
Age in years, mean (SD) 44.6 (14.0) 45.5 (12.9) 44.7 (12.5) 45.9 (13.2)
Female 1489 (43.5) 565 (41.8) 1323 (40.4) 377 (37.9)
Waist circumference in cm, mean (SD) 99.7 (17.1) 101.7 (16.6) 101.2 (16.8) 104.7 (19.0)
BMI category, n (%)
Underweight (<18.5 kg/m2) 43 (1.3) 17 (1.3) 22 (0.7) 8 (0.8)
Normal (18.5e24.9 kg/m2) 677 (19.8) 236 (17.5) 546 (16.7) 149 (15.0)
Overweight (25.0e29.9 kg/m2) 1071 (31.3) 408 (30.2) 1031 (31.5) 262 (26.4)
Obese I (30.0e34.9 kg/m2) 735 (21.5) 296 (21.9) 787 (24.1) 211 (21.2)
Obese II (35.0e39.9 kg/m2) 345 (10.1) 178 (13.2) 381 (11.6) 141 (14.2)
Obese III (40 kg/m2) 279 (8.2) 107 (7.9) 275 (8.4) 141 (14.2)
Comorbidities and risk factors1
No comorbidity 1323 (38.7) 377 (27.9) 1016 (31.1) 323 (32.5)
1e2 comorbidities 1585 (46.3) 689 (51.0) 1636 (50.0) 436 (43.9)
3e4 comorbidities 416 (12.2) 233 (17.2) 513 (15.7) 178 (17.9)
5 comorbidities 97 (2.8) 53 (3.9) 106 (3.2) 57 (5.7)
Hypertension 620 (18.1) 390 (28.8) 782 (23.9) 259 (26.1)
Past TB 21 (0.6) 22 (1.6) 29 (0.9) 8 (0.8)
Diabetes mellitus 254 (7.4) 135 (10.0) 251 (7.7) 112 (11.3)
Dyslipidemia 307 (9.0) 143 (10.6) 334 (10.2) 120 (12.1)
Asthma 361 (10.6) 137 (10.1) 340 (10.4) 120 (12.1)
COPD 69 (2.0) 17 (1.3) 45 (1.4) 26 (2.6)
Immunodeficiency syndromes 6 (0.2) 4 (0.3) 1 (0.0) 4 (0.4)
Number of cigarettes smoked per day, mean (SD) 4.6 (7.7) 4.0 (7.1) 3.8 (6.8) 3.8 (7.1)
Alcohol units per week, mean (SD) 7.7 (12.1) 9.4 (17.1) 8.4 (13.4) 7.7 (12.8)
Disease
Disease duration in years, median (IQR) 18.0 (18.0) 21.0 (18.0) 20.0 (17.0) 20.0 (19.0)
Baseline PASI score, median (IQR) 14.1 (7.9) 13.8 (7.8) 14.3 (8.6) 14.6 (8.1)
Inflammatory arthritis 363 (10.6) 316 (23.4) 819 (25.0) 158 (15.9)
Concomitant treatments, n (%)
Any exposure to methotrexate during follow-up 2,118 (61.9) 229 (16.9) 572 (17.5) 83 (8.4)
Any exposure to cyclosporine during follow-up 1,216 (35.6) 104 (7.7) 225 (6.9) 38 (3.8)
Any exposure to acitretin during follow-up 970 (28.4) 48 (3.6) 71 (2.2) 27 (2.7)
Any exposure to fumaric acid esters during follow-up 552 (16.1) 26 (1.9) 30 (0.9) 5 (0.5)
Any exposure to hydroxycarbamide during follow-up 56 (1.6) 6 (0.4) 17 (0.5) 10 (1.0)
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; PASI, Psoriasis Area and Severity Score;
SD, standard deviation; TB, tuberculosis.
1List of predefined comorbidities includes hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic obstructive pulmonary disease,
peptic ulcer disease, chronic renal disease, liver disease, previous tuberculosis, demyelination, diabetes mellitus, impaired glucose tolerance, depression,
dyslipidemia, nonskin cancer, immunodeficiency syndromes, and thyroid disease.
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536therapies for ustekinumab (HR ¼ 2.18, 95% CI ¼
0.95e5.01, Table 3) and a nonstatistically significant
decrease between 1 year and 2 years of treatment (HR ¼
0.73, 95% CI ¼ 0.35e1.53).
The use of concomitant immunosuppressive therapy was
not associated with an increase in the risk of serious infection
(HR ¼ 1.09, 95% CI ¼ 0.70e1.68).
Sensitivity analyses
Analysis on a restricted cohort of entry year after 2009, the
time period when all of the biologic therapies were
available to be prescribed, found that the incidence rates
and HRs were similar to the figures reported in the main
analysis (see Supplementary Tables S6 and S7 online). The
sensitivity analysis using methotrexate as the comparatorJournal of Investigative Dermatology (2018), Volume 138found no statistically significant difference in the risk for
serious infections for etanercept, adalimumab, and uste-
kinumab, although the effect estimates were higher
(Table 3). The sensitivity analysis using a combined bio-
logic cohort also did not show a statistically significant
difference between the biologic and non-biologic or
methotrexate therapies (Table 3).
The same inverse probability treatment-weighted multi-
nomial model involving the non-biologic therapies, eta-
nercept, adalimumab, and ustekinumab was rerun using
the respective biologic therapies as the comparator instead
of the non-biologic cohort, and there was no significant
statistical difference found between the biologic therapies
(see Supplementary Table S8 online). The sensitivity anal-
ysis models involving methotrexate and the different
Table 2. Crude incidence rates of first serious
infection: overall, lower respiratory tract infections,
skin and soft tissue infections
Treatment (n)
Total Person-
Time, (Median
Follow-Up Time)
in Years Infections
Rate per
1,000
Person-
Years
95%
Confidence
Interval in
Person-Years
All serious infections
Non-biologics
(3,421)
6,419.24 (1.51) 91 14.18 11.54e17.41
Methotrexate
(2,118)
3,422.40 (1.27) 41 11.98 8.82e16.27
Etanercept
(1,352)
3,278.20 (1.87) 50 15.25 11.56e20.12
Adalimumab
(3,271)
7,835.17 (1.97) 108 13.78 11.41e16.64
Ustekinumab
(994)
2,256.44 (2.00) 34 15.07 10.77e21.09
Lower respiratory tract infections
Non-biologics — 27 4.21 2.88e6.13
Methotrexate — 14 4.09 2.42e6.91
Etanercept — 18 5.49 3.46e8.71
Adalimumab — 31 3.96 2.78e5.63
Ustekinumab — 12 5.32 3.02e9.36
Skin and soft tissue infections
Non-biologics — 22 3.43 2.26e5.20
Methotrexate — 10 2.92 1.57e5.43
Etanercept — 12 3.66 2.08e6.45
Adalimumab — 19 2.42 1.55e3.80
Ustekinumab — 8 3.55 1.77e7.09
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proportionality assumption.
DISCUSSION
We did not observe any statistically significant increases in
the risk of serious infection for any biologic therapy versus
non-biologic systemic therapies in patients with psoriasis. We
show that etanercept, adalimumab, and ustekinumab have
no significant differential risk of serious infection. In terms of
the clinical relevance of the precision of our estimated risk,
we were able to rule out a 1.6-fold increase in serious
infection risk for etanercept and rule out a lower serious
infection risk for adalimumab and ustekinumab over
non-biologic systemic therapies. We found that the relative
risk of serious infection between ustekinumab and the non-
biologic systemic therapies was not constant over time.
We did not observe any association between the use of
concomitant immunosuppressive therapy and increase in the
risk of serious infection. However, the propensity score
method balances the baseline characteristics and not time-
varying factors, and hence it cannot deal adequately with
confounding by indication for the use of concomitant
immunosuppressive therapy. This estimated result should
therefore be interpreted with caution.
Strengths and limitations
The major strengths of this study are the prospective
cohort study design, the large sample size, fullyindustry-independent data analysis, and the participation of
multiple dermatology centers (153) in the UK and Republic
of Ireland. To our knowledge, this study is the largest single
registry cohort study assessing the serious infection risk of
first-line biologic therapies for the treatment of psoriasis to
date. Detailed data capture allowed for the inclusion of
numerous covariates relevant to the risk of infection in the
propensity score.
The accuracy of detailed information about the infection is
dependent on information from the recruiting dermatology
center. Recall bias may occur with patient-reported charac-
teristics; this is likely to be nondifferential between the
comparator treatments. Selection bias introduced by non-
randomization is controlled for by propensity score weight-
ing for the variables that were available, but variables that
were not measured and not known to be associated with the
exposure or the outcome could have potentially introduced
residual confounding. For example, we were not able to
adjust for previous serious infection within the past year.
We included a large cohort of patients receiving metho-
trexate, the most prevalent non-biologic systemic therapy in
BADBIR, as a single non-biologic comparator to maximize
interpretability and comparison against published literature.
We also used the non-biologic systemic therapies as a
grouped comparator to increase the precision of the esti-
mated risk of serious infection of the biologic therapies,
which are reflected in the tighter confidence intervals
compared with the methotrexate-only comparator estimates.
Comparisons with other studies and important differences in
results
We found that the distribution of the site of common
infections, which included lower respiratory tract infections,
skin or soft tissue infections, urinary tract infections, and
abdominal infections, were similar between the non-biologic
and the biologic therapies studied. This is similar to the
serious infections reported in a large Dutch study of patients
with psoriasis, most of whom were not receiving biologic
therapies (Wakkee et al., 2011), and the results from the
Psoriasis Longitudinal Assessment and Registry (PSOLAR), a
large, single pharmaceutical company-sponsored study
based mainly in the US and Europe, which reported pneu-
monia and cellulitis as the two most common serious in-
fections in patients with psoriasis receiving non-biologic and
biologic therapies (Kalb et al., 2015).
There are large variations in the reported crude incidence
rate of serious infection in patients with psoriasis on biologic
therapies. Our reported incidence rates for etanercept and
adalimumab are similar to those reported by the PSOLAR
registry (Kalb et al., 2015) and are similar to that reported for
TNFIs overall in the Psocare Italian registry (Garcia-Doval
et al., 2017a). Our incidence rate for serious infections with
ustekinumab is higher than the PSOLAR (ustekinumab is the
drug marketed by the sole sponsor of the registry) and
Spanish Registry of Adverse Events from Biological Therapy in
Psoriasis (i.e., BIOBADADERM) rates (Davila-Seijo et al.,
2017): (BADBIR, 15.1; PSOLAR, 8.3; Spanish Registry of
Adverse Events from Biological Therapy in Psoriasis, 5.9 per
1,000 person-years). These variations are to be expected,
given the differences in the health care systems around thewww.jidonline.org 537
Table 3. Crude Cox proportional hazards model and adjusted model using inverse probability treatment weighting
by propensity score, showing hazard ratios from a multinomial model involving etanercept, adalimumab, and
ustekinumab versus non-biologic therapy1
Etanercept Adalimumab Ustekinumab All Biologics
Comparison against all non-biologic systemic therapies, hazard ratios (95% confidence intervals)
Crude 1.11 (0.79e1.57) 0.98 (0.74e1.29) 1.04 (0.70e1.54) 1.02 (0.80e1.31)
Adjusted 1.10 (0.75e1.60) 0.93 (0.69e1.26) 0.92 (0.60e1.41) 0.96 (0.73e1.27)
Concomitant immunosuppressants 1.05 (0.67e1.64) 1.09 (0.70e1.68)
Adjusted 0e6 months — — 2.18 (0.95e5.01) —
Adjusted 6e12 months — — 1.20 (0.51e2.81) —
Adjusted 1e2 years — — 0.73 (0.35e1.53) —
Comparison against methotrexate
Crude 1.37 (0.90e2.07) 1.19 (0.83e1.71) 1.26 (0.80e1.99) 1.31 (0.94e1.84)
Adjusted 1.47 (0.95e2.28) 1.26 (0.86e1.84) 1.22 (0.75e1.99) 1.29 (0.90e1.85)
Concomitant immunosuppressants 1.00 (0.64e1.57) 1.04 (0.67e1.62)
1Exposure time with concomitant (methotrexate, cyclosporine, fumaric acid esters, hydroxycarbamide) immunosuppressive medication use is adjusted for,
with exposure time to two immunosuppressive therapies classed as concomitant in the non-biologic cohort.
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538world and therefore propensity for hospitalization, a defining
factor for the classification of an infection as serious.
Different national clinical guidelines and funding/
reimbursement arrangements may also introduce channeling
effects toward certain treatments.
We found similar results to those of the PSOnet collabo-
ration, a network of European registries of patients with
psoriasis, which reported no increased risk of serious infec-
tion with TNFIs compared with a cohort receiving either
acitretin, methotrexate, or cyclosporine in a meta-analysis of
psoriasis treatment registries across Europe. A smaller study
from Spanish Registry of Adverse Events from Biological
Therapy in Psoriasis, with a focus on nonserious infections,
showed no statistically significant increased risk for serious
infections with TNFIs or ustekinumab versus methotrexate
(Davila-Seijo et al., 2017). In contrast, an increased risk of
serious infection with adalimumab was reported compared
with acitretin or phototherapy in the PSOLAR registry, with
similar results reported in a sensitivity analysis including
methotrexate in the comparator cohort (Kalb et al., 2015).
These observational studies have different specific limita-
tions that impede clinical interpretation. The merger of
exposure to three different TNFIs (with different molecular
structures, induction regimens, dosing schedule, and drug
administration) into one cohort masks important distinctions
between the drugs, thereby limiting the ability to inform
patient choice for any particular biologic therapy (Garcia-
Doval et al., 2017a). The Spanish registry lacked power to
investigate serious infections (Davila-Seijo et al., 2017), and
the study from the PSOLAR registry did not measure impor-
tant covariates (e.g., Psoriasis Area and Severity Index, the
tool used for measuring disease severity in clinical trials for
psoriasis, and concomitant use of immunosuppressants),
which may have led to significant residual confounding (Kalb
et al., 2015) and excluded important comparators, such as
cyclosporine as an alternative treatment for patients with
severe psoriasis in the real world.
We believe that the use of a Cox regression survival anal-
ysis model avoids unrealistic assumptions of a constant rate
and independent recurrent events that the use of a Poisson
model would introduce. Only 35 of 283 (12%) of participantsJournal of Investigative Dermatology (2018), Volume 138suffered from recurrent events, and on the balance we chose
to restrict our outcome to the first serious infection to maxi-
mize interpretability with little loss in statistical power.
In contrast with our findings, TNFIs have been shown to be
associated with serious infections in rheumatoid arthritis and
in a time-dependent manner, with relative risks between 1.2
and 1.8 (Askling et al., 2007; Galloway et al., 2011;
Strangfeld et al., 2011). However, a comparison of data
from psoriasis and rheumatoid arthritis patient registries
found that psoriasis patients were associated with approxi-
mately half the risk of serious adverse events (Garcia-Doval
et al., 2017b); thus, safety data cannot be directly extrapo-
lated between these two patient populations. Use of
concomitant immunosuppressants, particularly systemic
corticosteroids, is greater in the rheumatoid arthritis popu-
lation compared with the psoriasis population and may drive
some of this increased risk (Askling et al., 2007; Galloway
et al., 2011; Strangfeld et al., 2011).
Implications for patients, clinicians, and policymakers
Our results suggest that the risk of serious infection should
not be a key discriminator for patients and clinicians when
choosing between non-biologic systemic therapies,
etanercept, adalimumab, and ustekinumab. The recently
updated British Association of Dermatologists guideline for
biologic therapies in psoriasis, widely used by dermatologists
around the world, recommends adalimumab and ustekinu-
mab as first-line biologic therapies (along with secukinumab)
and relegates etanercept to use as a second-line biologic
therapy (Smith et al., 2017). This decision was based pre-
dominantly on evidence for efficacy from clinical trials
(Jabbar-Lopez et al., 2017). There is a perception that
etanercept has a lower risk of serious infection than other
biologics based on lower rates of tuberculosis, extrapolation
from the rheumatoid arthritis literature (Galloway et al.,
2011), and the general assumption that a less efficacious
tumor necrosis factor inhibitors would be safer. Our results
further reinforce the treatment hierarchy as suggested by the
British Association of Dermatologists guidelines. It was
reassuring that the distribution of types of infections was
similar between the biologic and non-biologic cohorts.
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serious infection associated with biologic therapies.
Future research opportunities
There were low rates of 30-day mortality due to serious
infection for the etanercept and non-biologic cohorts, and
there were no deaths in either the adalimumab or ustekinu-
mab cohorts. This may be a result of selection bias, with
channeling of patients with more comorbidities and hence
higher risk of death risk to the treatments with a lower
perceived risk. Investigation within a larger cohort and with a
longer follow-up period is welcomed to investigate whether
there is any association between infection-related 30-day
mortality and the different therapies.
Summary
We did not find a statistically significant higher relative risk of
serious infections for etanercept, adalimumab, and usteki-
numab compared with non-biologic therapies for patients
with psoriasis. There was no difference in the risk of serious
infections between etanercept, adalimumab, and ustekinu-
mab. The risk of serious infection, therefore, should not be a
primary concern for patients and clinicians when deciding
between non-biologic systemic therapies or these three bio-
logic therapies for psoriasis. Health care professionals should
be equally vigilant for serious infections when managing
patients with psoriasis who are receiving either systemic
non-biologic or biologic therapies.
MATERIALS AND METHODS
BADBIR was approved in March 2007 by the National Health Ser-
vice Research Ethics Committee North West England, reference 07/
MRE08/9. All subjects gave written informed consent for their
participation in the registry.
BADBIR is a large, ongoing, prospective pharmacovigilance reg-
istry of psoriasis patients that was established in 2007 in the UK and
Ireland to compare the safety of biologic therapies against non-
biologic systemic therapies. Establishing the risk of serious
infections was a prespecified primary aim of the registry. The design
of BADBIR (Burden et al., 2012) and the baseline patient charac-
teristics (Iskandar et al., 2015) have been published previously. In
England, the National Institute for Health and Care Excellence rec-
ommends that all patients with psoriasis receiving biologic therapies
should be registered on BADBIR. Subjects were selected in a data
snapshot from October 2016.
Baseline assessment
Baseline data were collected before or during the initial 6 months of
treatment. Drug, clinical, and comorbid history along with anthro-
pometric data were collected by a health care professional using a
web-administered questionnaire, and lifestyle factors were collected
by a patient completed questionnaire.
Follow-up assessments
Data from patients were collected every 6 months for the first 3
years, then annually thereafter to 10 years. Follow-up data were
collected and entered onto a web-based system contemporaneously.
Specific information about serious infections was collected,
including descriptions of events, hospitalization, and start and stop
dates. Patient death information was collected from BADBIR and
validated using the Office of National Statistics mortality records.
Additional external data on serious infections in Wales was providedby the National Health Service Welsh Informatics Service and linked
onto BADBIR (12 additional events obtained). Adverse events were
classified using the Medical Dictionary for Regulatory Activities
system.
Data analysis
The main inclusion criteria for this study were biologic-naı¨ve
patients with chronic plaque psoriasis starting either a licensed
biologic therapy for psoriasis (i.e., etanercept, adalimumab, and
ustekinumab), who were recruited into the biologic cohort, and
biologic-naı¨ve patients with chronic plaque psoriasis receiving
either acitretin, psoralen-UVA, cyclosporine, fumaric acid esters,
methotrexate, and hydroxycarbamide, who were recruited into the
non-biologic systemic cohort. Secukinumab was excluded because
there were not enough patients receiving the therapy for meaningful
analysis at data lock (n ¼ 12) (Figure 1). Infliximab was considered to
be significantly different from both the non-biologic cohort and the
other three biologic therapies, given the higher prescription criteria
(Psoriasis Area and Severity Score  20 and Dermatology Life
Quality Index > 18) stipulated by the National Institute for Health
and Care Excellence, and power to study infliximab was also limited
(n ¼ 105). An initial exploratory analysis also confirmed these
findings, because the cohort receiving infliximab had a higher dis-
ease severity and more comorbidities compared with the non-
biologic and other biologic cohorts (see Supplementary Table S9
online).
Patients were included if follow-up data were available. No bio-
similar drugs were included in this study. Patients in the biologic
cohort contributed follow-up time from the first dose of the drug
until the first event of the following: serious infection, discontinua-
tion of treatment due to other reasons, last registered follow-up,
switch to other biologic therapy, or death. Patients in the non-
biologic cohort contributed follow-up time from first dose of the
index drug until the first event of all of the mentioned events but
were censored at the end of the last alternative non-biologic therapy.
Patients who switched from the non-biologic therapy cohort to start
receiving a biologic therapy contributed follow-up time to both
cohorts. Second or subsequent lines of biologic therapy were not
eligible for this study.
A serious infection was defined as any infection that was associ-
ated with or prolonged hospitalization, required the use of intrave-
nous antimicrobial therapy, or led to death. The inclusion of
intravenous antimicrobial therapy use is a pragmatic addition to the
International Conference on Harmonisation definition of serious
adverse event specific to infections. The events were validated by
separate review from two clinicians (ZZNY, RBW) against these
criteria, and discrepancies (n ¼ 41) were resolved through discus-
sion. A clinical specialist relevant to the specific type of infection
was consulted in cases for which there was uncertainty. The first
serious infection was included for analysis in this study, with a risk
window period of 90 days after cessation of treatment applied for the
attribution of the event to the drug (Galloway et al., 2011).
The licensed dosing regimens for the biologic therapies are as
follows: etanercept 50 mg once weekly by subcutaneous injection,
adalimumab 40 mg every other week starting 1 week after an initial
dose of 80 mg by subcutaneous injection, and ustekinumab 45 mg
(90 mg for patients of 100 kg or greater) initially, at week 4, week 12,
and every 12 weeks thereafter by subcutaneous injection adminis-
tered by health care professionals. The impact of alternate dosing
regimens was not analyzed because the proportion of patients usingwww.jidonline.org 539
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in the UK (<15% [Iskandar et al., 2017]), and National Institute for
Health and Care Excellence-approved dosing regimen is according
to the license. Within the biologic cohort, the number of person-
years receiving doses outside the license was too low to make sta-
tistical inferences for the effect of dosing regimen on the risk of
serious infection.
Sample size was based on detecting or ruling out a 2-fold increase
in serious infection risk as compared with the non-biologic systemic
cohort, which was considered a clinically relevant difference by
consensus of the BADBIR data analysis committee.
Primary analyses
To provide a description of the rates of serious infections, crude
incidence rates for each drug in the biologic cohort and the non-
biologic cohort were calculated as the number of events per 1,000
patient-years of follow-up. Survival modeling with Cox proportional
hazards was used to compare event rates and estimate the effect of
each exposure on the risk of serious infections.
A priori potential confounders to include in the multivariate
analysis were based on expert opinion and a literature review (Yiu
et al., 2016). These were age, sex, body mass index, waist circum-
ference, alcohol use, disease severity (Psoriasis Area and Severity
Index), concomitant inflammatory arthritis including psoriatic
arthritis and ankylosing spondylitis, smoking, diabetes, chronic
obstructive pulmonary disease, asthma, immunodeficiency syn-
dromes, and concomitant immunosuppressants. The total number of
measured comorbidities was included as a separate covariate as a
proxy for patient frailty. Conditions under immunodeficiency syn-
dromes include HIV infection and lymphopenia. Body mass index
was presented as a categorical variable to ease data description in
Table 1 but was kept as a continuous variable in the statistical
models. Adjustment for the baseline potential confounders was
performed using a propensity score model. A probability score for
having the treatment was derived from a multinomial logistic
regression model based on the baseline-relevant covariates listed.
The use of propensity score adjustment has various advantages over
multivariable regression models, in particular the ability to check the
balance of measured confounders between the comparator cohorts,
and improving estimation when outcome is rare by allowing for
multiple covariates (Glynn et al., 2006).
Inverse probability treatment weighting, where the treatments
were weighted for the distribution of the propensity score in the
whole model cohort, was then performed using propensity score
probabilities in both models. Balance between groups after
weighting was assessed using expected bias from a logistic regres-
sion model estimating the effect of the variable on serious infection.
Improvement in balance was achieved by an iterative process of
fitting interaction terms involving the least balanced variables.
Concomitant therapies that were considered to be immunosup-
pressants were methotrexate, cyclosporine, fumaric acid esters, and
hydroxycarbamide. Concomitant immunosuppressants (defined as
the exposure period to more than one immunosuppressant in the
non-biologic cohort) were treated exceptionally as time-varying
covariates, allowing for the time on and off these drugs throughout
follow-up.
Missing data (see Supplementary Table S10 online) were imputed
in a multiple imputation model of 20 cycles to reduce bias (Sterne
et al., 2009). We used multiple imputation to account for missing
data for the potential confounders, because this preserves theJournal of Investigative Dermatology (2018), Volume 138variability and uncertainty of the missing data and avoids the loss of
power and bias that alternative ad hoc methods, such as a complete
case analysis, may introduce. Propensity likelihood scores were
calculated in each imputed dataset and combined after regression
modeling using Rubin’s rules. A key assumption for the Cox
regression is the proportionality assumption, where the relative risk
between the comparators is constant over time. Formal testing for
proportionality using Schoenfeld residuals in the Cox regression
model was performed in five extracted imputed datasets, and where
the proportionality assumption did not hold a time-stratified analysis
using the prespecified time points of 0e6 months, 6e12 months,
and 12e24 months of follow-up, which were the designated follow-
up data reporting time points, was performed.
Secondary analyses
A priori planned sensitivity analyses included methotrexate users as
the comparator cohort as the most common systemic non-biologic
in use, combining all three biologic cohorts as one cohort to
compare against all non-biologic systemic therapies and metho-
trexate, and restriction to patients starting treatment on or after 2009
(when the three biologic therapies were available for prescription at
the same time). Descriptive analysis was performed on soft tissue
and skin infections, and lower respiratory tract infections as these
were identified as common infections associated with patients
receiving biologic therapies, but the lower number of events did not
allow for meaningful multivariate analysis of relative risks (see
Supplementary Table S2).
The actual number of events for any data point involving the
individual biologic therapies that has fewer than five events in the
descriptive analysis has been removed for the protection of partici-
pant confidentiality. All analyses were performed using Stata 14
(StataCorp, College Station, TX).
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